OTLC
Oncotelic Therapeutics, Inc.
Key Financials
Operating Income
$-3186599
↑ 10.9%
Revenue
$70000
0.0%
Net Income
$249.3M
↑ 5610.2%
Total Liabilities
$131.4M
↑ 584.2%
EPS (Diluted)
$0.59
↑ 6000.0%
Shareholders' Equity
$262.8M
↑ 3084.3%
Total Assets
$393.1M
↑ 1373.5%
Cash & Equivalents
$170405.00
↓ 29.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 4 | 7/23/2026 | View on SEC |
| D | 7/22/2026 | View on SEC |
| 4 | 7/21/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
| 4 | 7/14/2026 | View on SEC |
| 4 | 7/14/2026 | View on SEC |
| 4 | 7/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OTLC |
| Company Name | Oncotelic Therapeutics, Inc. |
| CIK | 908259 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-635-7000 |